Kolexia
Bennamoun Mostefa Oncologie médicale
Bennamoun Mostefa
Oncologie médicale
Institut Mutualiste Montsouris
Paris, France
91 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Carcinomes Tumeurs colorectales Métastase tumorale Tumeurs prostatiques résistantes à la castration Néphrocarcinome Tumeurs du foie Tumeurs du rein Adénocarcinome

Collaborateurs

Voir plus
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France
Louvet Christophe
Louvet Christophe
Institut Mutualiste Montsouris, Paris, France
Thibault Constance
Thibault Constance
Hôpital Européen Georges Pompidou, Paris, France
Helissey Carole
Helissey Carole
Hopital Instruction des Armees Begin, Saint-Mandé, France

Industries

Voir plus
Janssen
32 collaboration(s)
Dernière en 2023
Ipsen
21 collaboration(s)
Dernière en 2023
BMS
13 collaboration(s)
Dernière en 2023
Sanofi
11 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer: A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (MacroGenics)   18 mars 2024
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Cell reports. Medicine   14 novembre 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Cancer research   05 septembre 2023
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research   04 avril 2023
Abstract 1342: Roles of mesenchymal-like tumour cells and myofibroblastic cancer-associated fibroblasts in progression and therapeutic response of clear-cell renal cell carcinoma
Proceedings: AACR Annual Meeting 2023   01 avril 2023
PEACE2: A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Essai Clinique (Sanofi)   28 octobre 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
European urology open science   17 septembre 2022